Global perspectives on vaccine financing

Expert Review of Vaccines

Volumn 3, Issue 5, 2004, Pages 557-562

  Berman, Stephen ^a,b   Giffin, Robert B ^c  

^a CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF MEDICINE   (United States)

Author keywords

Financing; Pricing; Research and development; Schedule divergence; Vaccines

Indexed keywords

ANTIULCER AGENT; BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VACCINE;

ADULT; BUDGET; CHILD; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; INFECTION; INFECTION PREVENTION; INVESTMENT; MEASLES; MONEY; PRIORITY JOURNAL; PROFIT; REVIEW; UNITED STATES; VACCINATION; WORLD HEALTH ORGANIZATION;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG DESIGN; DRUG INDUSTRY; FINANCING, GOVERNMENT; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; RESEARCH SUPPORT; UNITED STATES; VACCINES; WORLD HEALTH;

EID: 7444234862     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.5.557     Document Type: Review

References (16)

1. Barks-Ruggles E. The globalization of disease: when Congo sneezes, will California get a cold? Brooking Rev. 19(4), 30-33 (2001).
2. Institute of Medicine. Vaccines for the 21st Century: a Tool for Decision making. National Academy Press, Washington, DC, USA (2000).
3. World Health Organization. The World Health Report, 1999: Making a Difference. World Health Organization, Geneva, Switzerland (1999).
4. World Health Organization. Assessing the Global Needs for Vaccine Research and Development. World Health Organization, Geneva, Switzerland (2000).
5. United Nations Children's Fund. Vaccine Security: Ensuring a Sustained, Uninterrupted Supply of Affordable Vaccines. UNICEF, NY, USA (2002).
6. Mercer Management Consulting. Lessons Learned: New Procurement Strategies for Vaccines: Final Report to the GAVI Board. Mercer Management Consulting, IL, USA (2002).
7. Batson A. Understanding the Vaccine Market and Its Economics: Obstacles and Potential Solutions. Presentation to the Out of the Box Group, 26th July (2001).
8. Grabowski H, Vernon J. The Search for New Vaccines: the Effects of the Vaccines for Children Program. AEI Press, DC, USA (1997).
9. General Accounting Office. Childhood Vaccines: Ensuring an Adequate Supply Poses Continuing Challenges. US General Accounting Office, DC, USA (2002).
10. Institute of Medicine. Financing Vaccines in the 21st Century: Assuring Access and Availability. National Academy Press, Washington, DC, USA (2004).
11. Hay J, Zammit D. Vaccine Policy Perspectives: Market Strategies. Institute of Medicine, Public Access File (2003).
12. Clarke B. Strengthening the supply of routinely recommended vaccines in the US. Presentation to the National Vaccine Advisory Committee, Washington, DC, USA, 11th February (2002).
13. DeMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 325-330 (2003).
14. Taylor C, Cutts F, Taylor M. Ethical dilemmas in current planning for polio eradication. Am. J. Public Health 87(6), 922-925 (1997).
15. Finkelstein A. Health Policy and Technological Change: Evidence from the Vaccine Industry. Working Paper 9460. National Bureau of Economic Research, Cambridge, MA, USA (2003).
16. Arnould R, DeBrock L. An Overview of the Market for Vaccines in the United States, Institute of Medicine, Public Access File (2002).